Formycon AG
FYB
Rank in Stocks
#15003
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly... Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
Share Price
$16.27
Last synced: 2026-11-09
Market Cap
$287.59M
Change (1 day)
3.53%
Change (1 year)
-34.52%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Formycon AG (FYB)
Category
Healthcare
EPS for Formycon AG (FYB)
EPS as of June 2026 TTM: $-1.58
According to Formycon AG's latest financial reports, its current EPS (TTM) is $-1.58. At the end of 2025 the company had an EPS of $-4.29, an increase over its 2024 EPS of $-7.47.
EPS history for Formycon AG from 2009 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.58 | -63.09% |
| 2025 | $-4.29 | -42.52% |
| 2024 | $-7.47 | -241.99% |
| 2023 | $5.26 | 87.23% |
| 2022 | $2.81 | -305.95% |
| 2021 | $-1.36 | 69.77% |
| 2020 | $-0.80 | 211.43% |
| 2019 | $-0.26 | -129.95% |
| 2018 | $0.86 | -522.50% |
| 2017 | $-0.20 | -56.92% |
| 2016 | $-0.47 | -785.24% |
| 2015 | $0.07 | -42.70% |
| 2014 | $0.12 | -111.39% |
| 2013 | $-1.06 | 234.46% |
| 2012 | $-0.32 | 88.12% |
| 2011 | $-0.17 | 25.88% |
| 2010 | $-0.13 | 125.08% |
| 2009 | $-0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,088.95% |
US
|
|
| $-7.07 | 346.48% |
US
|
|
| $-5.29 | 234.07% |
AU
|
|
| $12.88 | -913.39% |
BE
|
|
| $21.56 | -1,461.54% |
NL
|
Questions about Formycon AG's earnings per share (EPS)
What is Formycon AG's earnings per share (EPS)?
Formycon AG's earnings per share (EPS) over the last twelve months is $-1.58, as of Jun 2026.
What was Formycon AG's earnings per share (EPS) in 2025?
In 2025, Formycon AG's earnings per share (EPS) was $-4.29, compared with $-7.47 in 2024.
How has Formycon AG's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Formycon AG's earnings per share (EPS) was highest in 2023 ($5.26) and lowest in 2024 ($-7.47).
How does Formycon AG's earnings per share (EPS) compare with similar companies?
Formycon AG's earnings per share (EPS) ($-1.58) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.